This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


EndoBarrier Therapy to be Featured at Digestive Disease Week


LEXINGTON, Mass.—GI Dynamics announced today that EndoBarrier® Therapy, a treatment for type 2 diabetes and/or obesity, will be the subject of several presentations and scientific sessions during Digestive Disease Week 2012 (DDW), which takes place May 19-22 in San Diego.

“There is ongoing interest in the use of EndoBarrier Therapy as demonstrated by the number of presentations offered at DDW and other medical conferences," said Mark C. Twyman, chief commercial officer, GI Dynamics, Inc. “Patients with type 2 diabetes and/or obesity across the globe have achieved significant health improvements and treatment outcomes as a result of EndoBarrier Therapy. DDW is the world’s largest gathering of physicians and researchers in the fields of gastroenterology, endoscopy and gastrointestinal surgery, and we look forward to sharing EndoBarrier demonstrations, clinical research and treatment insights with this important medical community."

Alex Escalona, MD, assistant professor of surgery, Department of Digestive Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile, will provide an overview of EndoBarrier Therapy and present a hands-on demonstration of the device at the workshop, “Xtreme Endoscopic Toolbox: New and Cutting Edge Therapies," on May 20.

“EndoBarrier is a thin, flexible, sleeve-like liner that works by creating a physical barrier between food and a portion of the intestinal wall," said Dr. Escalona. “With EndoBarrier Therapy, my patients report increased energy, feeling full for a longer period of time after eating, and immediate and continued weight loss. I look forward to sharing with my colleagues what EndoBarrier Therapy is, how it works, and how it is easily inserted and removed during this interactive session."

EndoBarrier Therapy affects certain gastrointestinal hormones involved in insulin sensitivity, glucose metabolism and satiety, and these changes allow for rapid and sustained improvement of type 2 diabetes and weight loss, GI Dynamics  reported.

EndoBarrier received CE Mark approval for Europe in 2010 as well as approval by the Therapeutic Goods Administration in Australia in 2011 for the treatment of type 2 diabetes and/or obesity. EndoBarrier is currently commercially available in select European markets, Chile and Australia.

comments powered by Disqus